MONTREAL, April 8 /PRNewswire/ - The PerOs team is proud to announce the USDA/CVB has granted PerOs an Establishment License for the production of bacterins as well as an autogenous bacterin license utilizing its patented oral delivery formulation methods (Oralject(TM)).
"The approval of our manufacturing facility and our oral vaccine formulation platform in the United States marks a significant milestone for our Company, and we look forward offering these capabilities to the livestock producers and opening new possibilities to the growing aquaculture market, as well as collaborating with traditional animal health companies to expand the oral enablement of the industry as a whole." said Grant Vandenberg, CSO and inventor of Oralject.
PerOs' oral delivery platform focuses on the use of natural products to provide delivery of safe therapeutic and prophylactic compounds. PerOs' formulations are designed to enable the delivery of biological compounds such as vaccines, peptides, and probiotics among others while eliminating the stress associated with handling, injection and other current delivery practices.
This new technology platform will enhance the value of vaccines by offering a labor-minimizing, practical oral delivery approach for the livestock industry and open up new possibilities to the rapidly growing aquaculture market. Oral vaccination will provide animal producers with an innovative tool for disease prevention through vaccination rather than relying on disease treatment using antibiotics.
PerOs' is excited to offer this unique tool to an industry focused on producing safe, healthy food for humans. "Oral delivery will improve the adoption of vaccine usage. Vaccination can now occur when appropriate for disease management rather than based on labor management." said Tom Overbay, Vice President Business Development.
PerOs' first-of-its-kind facility was made possible by the contribution of Benchmark Biolabs development team. Benchmark managed the regulatory interface and established the QA and QC standards while also designing, constructing and, today, operating the PerOs manufacturing facility.
"The work of the Benchmark team was perfect, using their BEAM process flow, they led our technology assets in record time toward regulatory approval." said Ian Kott, Chairman of the Board of PerOs.
PerOs is a U.S.-based biotechnology company that has developed unique formulation methods enabling oral delivery of biopharmaceutical compounds by using naturally occurring products to create a technology platform to break the barrier of bioavailability for oral delivery of complex bioactive compounds.
PerOs, Breaking the barriers of bioavailability
CONTACT: Jean-Simon Venne, PerOs Inc., (514) 516-3003,
firstname.lastname@example.org; Tom Overbay, DVM, Benchmark Biolabs, Inc, (402)